BCAL Diagnostics (ASX: BDX) — Company Overview, News & Financial Data
BCAL Diagnostics is an Australian biotechnology company focused on developing and commercialising non-invasive blood tests for early cancer detection.
BCAL Diagnostics
BCAL Diagnostics is an Australian biotechnology company focused on developing and commercialising non-invasive blood tests for early cancer detection. The company's lead product, BREASTEST plus, is a lipid biomarker-based diagnostic test designed to complement mammography, particularly for women with dense breast tissue where imaging results may be inconclusive. In addition to breast cancer screening, BCAL Diagnostics is expanding its diagnostic technology pipeline into research programs for the early detection of pancreatic and ovarian cancers. The company collaborates with clinical specialists, medical practitioners, and accredited pathology partners across Australia to integrate its blood testing solutions into routine healthcare.
Snapshot
Operations
Products and/or services of BCAL Diagnostics
- Breast Cancer Blood Diagnostics: Development and commercialisation of non-invasive lipid biomarker blood tests designed to complement standard mammography screening, assisting medical practitioners in ruling out breast cancer in patients over age 30 with dense breast tissue.
- Pancreatic Cancer Diagnostic Research: Early-stage research and development program focused on identifying non-invasive blood-based biomarkers for the early detection of pancreatic cancer, aiming to expand diagnostic technology capabilities into additional high-fatality oncology indications.
- Ovarian Cancer Diagnostic Research: Research initiative applying lipidomic diagnostic platforms to identify circulating blood biomarkers for ovarian cancer, targeting early clinical detection and improved diagnostic precision to complement conventional clinical assessment tools.
- Clinical Pathology & Collection Services: Strategic coordination with accredited pathology laboratories, clinical specialists, and regional blood collection centers to process patient samples, conduct lipidomic biomarker evaluations, and deliver diagnostic results to healthcare providers.
BCAL Diagnostics executive team
- Jayne Andrea ShawCo-Founder & Executive Chairman
- Anne-Louise ArnettChief Executive Officer
- Guy Adrian RobertsonCFO & Company Secretary
- Sean Alexander KennedyDirector of Corporate Finance
Latest news about BCAL Diagnostics
BCAL Diagnostics introduces multi-cancer test in Sydney, Melbourne
AustraliaGenetic Signatures responds to 10.2% BCAL Diagnostics stake
AustraliaBCAL Diagnostics secures extra A$4.9m to fund cancer detection portfolio
AustraliaBCAL Diagnostics develops breast cancer test with 91% sensitivity
AustraliaBCAL Diagnostics expands cancer test access nationwide
AustraliaBCAL Diagnostics appoints Anne-Louise Arnett as new CEO
Australia
Recent announcements
What BCAL Diagnostics (BDX) has told the market, newest first.
- Investor Presentation - Transforming Cancer Detection
- Change in substantial holding
- BCAL Develops New Blood Test for Breast Cancer RecurrencePrice sensitive
Dividend history
Dividends per share paid by BCAL Diagnostics, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $3.1500 |
| FY2025 | — | — | — | $3.2783 |
| FY2024 | — | — | — | $3.0582 |
| FY2023 | — | — | — | $2.8931 |
| FY2022 | — | — | — | $2.7506 |
Key financials
Reported results for BCAL Diagnostics, in AUD.
- Market cap
- 31M
- Revenue (TTM)
- 2.4M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 182.5K | -9.4M | -7.4M | |
| 21.6K | -10M | -7.2M | |
| 3.1M | -5.4M | -6.4M | |
| 2.8M | -4.7M | -5.1M |